Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKesson
Merck
Express Scripts
Mallinckrodt

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,889,661

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,889,661
Title:Treatment of lupus nephritis using laquinimod
Abstract: This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.
Inventor(s): Haviv; Asi (Kvutsat Shiller, IL), Tarcic; Nora (Modiin, IL)
Assignee: Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL)
Application Number:13/039,178
Patent Claims:1. A method of treating a subject afflicted with active lupus nephritis comprising administering to the subject daily between 0.5-1.0 mg of laquinimod or pharmaceutically acceptable salt thereof and between 1-3 g of mycophenolate mofetil, wherein the amount of laquinimod and the amount of mycophenolate mofetil when taken together are more effective to treat he subject than when each agent is administered alone.

2. The method of claim 1, wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium.

3. The method of claim 1, wherein the daily administration laquinimod or pharmaceutically acceptable salt thereof is effected orally.

4. The method of claim 1, wherein the amount of laquinimod administered is 0.5 mg/day.

5. The method of claim 1, wherein the amount of laquinimod administered is 1.0 mg/day.

6. The method of claim 1, wherein the daily administration of mycophenolate mofetil is effected orally.

7. The method of claim 1, wherein the amount of mycophenolate mofetil administered is 2 g/day.

8. The method of claim 1, further comprising administering to the subject an amount of a steroid.

9. The method of claim 8, wherein the administration of the steroid is daily administration.

10. The method of claim 8, wherein the administration of the steroid is effected orally and/or intravenously.

11. The method of claim 8, wherein the amount of steroid administered is 500 mg/day methylprednisolone.

12. The method of claim 8, wherein the amount of steroid administered is 40 mg/day prednisolone and/or prednisone.

13. The method of claim 1, further comprising administration of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), antimalarials, statins, cyclophosphamide, azathioprine, 6-mercaptopurine, abatacept, rituximab, belimumab, cyclosporine or other calcineurin inhibitors.

14. The method of claim 1, wherein the daily administration continues for at least 24 weeks.

15. The method of claim 1, wherein the subject is human.

Details for Patent 8,889,661

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL) 2030-03-03 RX search
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23   Start Trial Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL) 2030-03-03 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 001 2011-03-09   Start Trial Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL) 2030-03-03 RX search
Human Genome Sciences Inc. BENLYSTA belimumab INJECTABLE; INJECTION 125370 002 2011-03-09   Start Trial Teva Pharmaceutical Industries, Ltd. (Petach-Tikva, IL) 2030-03-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Colorcon
Mallinckrodt
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.